Early Intermittent Intensive Insulin Therapy as an Effective Treatment of Type 2 Diabetes (RESET-IT Main Trial)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 109 participants.

Also called NCT02192424

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 109 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02192424
Other papers using this trial's data
  • Determinants of sustained stabilization of beta-cell function following short-term insulin therapy in type 2 diabetes Nature communications, 2023-07-27 DOI, PubMed 37500612, PMC10374648 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02192424. Randomized; single masking; primary purpose treatment. Start 2014-07 (registry gives no type); primary completion 2020-08 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Early Intermittent Intensive Insulin Therapy as an Effective Treatment of Type 2 Diabetes (RESET-IT Main Trial)
Acronym
RESET-IT
Intervention (Drug)
Metformin alone
Intervention (Drug)
Metformin + Intermittent Insulin Therapy
Lead sponsor
Mount Sinai Hospital, Canada (class: other)
Collaborator
Canadian Institutes of Health Research (CIHR) (class: other government)

Record details

Record id
cardio:ct-nct02192424
Content hash
96e7b3dbe21d198ea37c1dff8f436a9b622725aa7a7883e4c1fcae3a68b53d53